Please use this identifier to cite or link to this item:
|Caveolin-1 in sarcomas: friend or foe?
|Sáinz Jaspeado, Miguel Guillermo
Martín Liberal, Juan Jesús
Lagares Tena, Laura
Mateo Lozano, Silvia
García del Muro Solans, Xavier
Tirado, Oscar M.
|Sarcomas represent a heterogeneous group of tumors with a complex and difficult reproducible classification. Their pathogenesis is poorly understood and there are few effective treatment options for advanced disease. Caveolin-1 is a multifunctional scaffolding protein with multiple binding partners that regulates multiple cancer-associated processes including cellular transformation, tumor growth, cell death and survival, multidrug resistance, angiogenesis, cell migration and metastasis. However, ambiguous roles have been ascribed to caveolin-1 in signal transduction and cancer, including sarcomas. In particular, evidence indicating that caveolin-1 function is cell context dependent has been repeatedly reported. Caveolin-1 appears to act as a tumor suppressor protein at early stages of cancer progression. In contrast, a growing body of evidence indicates that caveolin-1 is up-regulated in several multidrug-resistant and metastatic cancer cell lines and human tumor specimens. This review is focused on the role of caveolin-1 in several soft tissue and bone sarcomas and discusses the use of this protein as a potential diagnostic and prognostic marker and as a therapeutic target.
|Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.255
|It is part of:
|Oncotarget, 2011, vol. 2, num. 4, p. 305-312
|Appears in Collections:
|Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)
This item is licensed under a Creative Commons License